Skip to main content

Advertisement

SpringerLink
Log in

Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Sentinel lymph node biopsy (SLNB) is recommended when mastectomy is performed for ductal carcinoma in situ (DCIS). The role of SLNB for women with DCIS who undergo mastectomy following one or more attempts at breast-conserving surgery (BCS) is uncertain. We examined the upgrade rate and SLNB yield in women who converted to mastectomy after one or more attempts at BCS for DCIS.

Methods

All patients who underwent one or more attempts at BCS prior to conversion to mastectomy with SLNB for DCIS were identified. Margin status as the indication for mastectomy was confirmed, and comparisons were made between patients with/without upgrade on final pathology.

Results

From February 2006 to November 2012, a total of 233 patients underwent completion mastectomy following one or more attempts at BCS for positive/close margins (median age 50 years; range 34–84). The median number of BCS attempts was 1 (range 1–4). Overall, 20 (9 %) patients were upgraded on final pathology; 15 (6 %) stage I, and 5 (3 %) stage II (three micrometastasis, two macrometastasis). In two of five cases with a positive SLN, invasive carcinoma was not identified in the mastectomy specimen. The only factor associated with any upgrade was the presence of micropapillary DCIS (80 vs. 55 %, with and without upgrade; p = 0.03).

Conclusion

In this cohort of patients with DCIS who converted to mastectomy for positive/close margins after one or more attempts at BCS, 18 (8 %) would have required second-stage axillary surgery had an SLNB not been performed, and in two (1 %) patients, the SLN provided the only evidence of invasion. These findings support the recommendation for SLNB at the time of completion mastectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–41.

    Article  CAS  PubMed  Google Scholar 

  2. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260(1):119–28.

    Article  PubMed  Google Scholar 

  3. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83.

    Article  PubMed  Google Scholar 

  4. Guillot E, Vaysse C, Goetgeluck J, et al. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. Breast. 2014;23(2):97–103.

    Article  CAS  PubMed  Google Scholar 

  5. Mittendorf EA, Arciero CA, Gutchell V, et al. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg. 2005;62(2):253–7.

    Article  PubMed  Google Scholar 

  6. Osako T, Iwase T, Ushijima M, et al. Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ. Cancer Sci. 2014;105(5):576–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sato Y, Kinoshita T, Suzuki J, et al. Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management. Breast Cancer. 2015. doi:10.1007/s12282-015-0636-5.

    PubMed Central  Google Scholar 

  8. Tunon-de-Lara C, Chauvet MP, Baranzelli MC, et al. The role of sentinel lymph node biopsy and factors associated with invasion in extensive DCIS of the breast treated by mastectomy: the Cinnamome Prospective Multicenter Study. Ann Surg Oncol. 2015;22(12):3853–60.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Huo L, Sneige N, Hunt KK, et al. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006;107(8):1760–8.

    Article  PubMed  Google Scholar 

  10. Tan JC, McCready DR, Easson AM, et al. Role of sentinel lymph node biopsy in ductal carcinoma-in situ treated by mastectomy. Ann Surg Oncol. 2007;14(2):638–45.

    Article  PubMed  Google Scholar 

  11. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200(4):516–26.

    Article  PubMed  Google Scholar 

  12. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. Version 3. www.nccn.org (2015). Accessed 14 Oct 2015.

  13. Coromilas EJ, Wright JD, Huang Y, et al. The influence of hospital and surgeon factors on the prevalence of axillary lymph node evaluation in ductal carcinoma in situ. JAMA Oncol. 2015;1(3):323–32.

    Article  PubMed  Google Scholar 

  14. Nicholson S, Hanby A, Clements K, et al. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS. Eur J Surg Oncol. 2015;41(1):86–93.

    Article  CAS  PubMed  Google Scholar 

  15. Karam A, Stempel M, Cody HS 3rd, et al. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg. 2008;207(4):543–8.

    Article  PubMed  Google Scholar 

  16. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.

    Article  PubMed  Google Scholar 

  17. Ansari B, Ogston SA, Purdie CA, et al. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg. 2008;95(5):547–54.

    Article  CAS  PubMed  Google Scholar 

  18. Han JS, Molberg KH, Sarode V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J. 2011;17(3):223–9.

    Article  PubMed  Google Scholar 

  19. Leidenius M, Salmenkivi K, von Smitten K, et al. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol. 2006;94(5):380–4.

    Article  CAS  PubMed  Google Scholar 

  20. Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg. 2006;192(4):455–7.

    Article  PubMed  Google Scholar 

  21. Meretoja TJ, Heikkila PS, Salmenkivi K, et al. Outcome of patients with ductal carcinoma in situ and sentinel node biopsy. Ann Surg Oncol. 2012;19(7):2345–51.

    Article  CAS  PubMed  Google Scholar 

  22. Tada K, Ogiya A, Kimura K, et al. Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer. World J Surg Oncol. 2010;8:6.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Trentin C, Dominelli V, Maisonneuve P, et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast. 2012;21(5):635–40.

    Article  PubMed  Google Scholar 

  24. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657–63.

    Article  PubMed  Google Scholar 

  25. Donker M, Litiere S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054–9.

    Article  PubMed  Google Scholar 

  26. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14(3):754–63.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was funded in part through NIH/NCI Cancer Center Support Grant P30 CA008748.

Disclosure

Melissa Pilewskie, Maria Karsten, Julia Radosa, Anne Eaton, and Tari A. King have no conflicts of interest to disclose.

Author information

Author notes

    Authors and Affiliations

    1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

      Melissa Pilewskie MD, Maria Karsten MD, Julia Radosa MD & Tari A. King MD

    2. Department of Gynaecology and Obstetrics, Saarland University Hospital, Homburg, Germany

      Julia Radosa MD

    3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

      Anne Eaton PhD

    Authors
    1. Melissa Pilewskie MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Maria Karsten MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Julia Radosa MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Anne Eaton PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Tari A. King MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Melissa Pilewskie MD.

    Additional information

    Melissa Pilewskie and Maria Karsten contributed equally to this study and share first authorship.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Pilewskie, M., Karsten, M., Radosa, J. et al. Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?. Ann Surg Oncol 23, 2229–2234 (2016). https://doi.org/10.1245/s10434-016-5145-z

    Download citation

    • Received:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1245/s10434-016-5145-z

    Keywords

    Search

    Navigation